Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan

Glioblastoma multiforme (GBM) carries a dismal prognosis despite the current standard of multimodality treatments. Recent studies showed promising results to a regimen consisting of a VEGF inhibitor, (bevacizumab) and a topoisomerase I inhibitor (irinotecan) [BI] in recurrent GBM. However, those pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Almubarak, Mohammed, Newton, Michael, Altaha, Ramin
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648641/
https://www.ncbi.nlm.nih.gov/pubmed/19259336
http://dx.doi.org/10.1155/2008/942618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648641/
https://www.ncbi.nlm.nih.gov/pubmed/19259336
http://dx.doi.org/10.1155/2008/942618

Ejemplares similares